Princess Margaret Hospital/Ontario Cancer Institute and University of Toronto, Toronto, Ontario, Canada.
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S21-35. doi: 10.1177/1758834011422557.
The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This review provides an overview of the evidence to support c-MET or the HGF/c-MET signaling pathway as relevant targets for personalized cancer treatment based on high frequencies of c-MET and/or HGF overexpression, activation, amplification in non-small cell lung carcinoma (NSCLC), gastric, ovarian, pancreatic, thyroid, breast, head and neck, colon and kidney carcinomas. Additionally, the current knowledge of small molecule inhibitors (tivantinib [ARQ 197]), c-MET/HGF antibodies (rilotumumab and MetMAb) and mechanisms of resistance to c-MET-targeted therapies are discussed.
受体酪氨酸激酶 c-MET 和其配体肝细胞生长因子（HGF）调节多种细胞过程，刺激细胞增殖、侵袭和血管生成。这篇综述提供了支持 c-MET 或 HGF/c-MET 信号通路作为非小细胞肺癌（NSCLC）、胃癌、卵巢癌、胰腺癌、甲状腺癌、乳腺癌、头颈部癌、结肠癌和肾癌中基于 c-MET 和/或 HGF 过表达、激活、扩增的个体化癌症治疗相关靶点的证据概述。此外，还讨论了小分子抑制剂（tivantinib [ARQ 197]）、c-MET/HGF 抗体（rilotumumab 和 MetMAb）以及对 c-MET 靶向治疗的耐药机制的最新知识。
